Osteoporosis

raloxifene hydrochloride

  • ACTIVE SUBSTANCE: raloxifene hydrochloride
  • CONCENTRATION: 60 mg
  • PRESENTATION: 28 coated tablets

INDICATION:

Raloxifene hydrochloride is indicated for the prevention and treatment of osteoporosis in postmenopausal women and to reduce the risk of breast cancer in postmenopausal women with osteoporosis.

The number of vertebral fractures was reduced. Although the reduction in the incidence of other fractures is not significant, the risk of these fractures decreases with the use of raloxifene hydrochloride. Menopause symptoms, effects on the breasts and uterus, and cardiovascular risks and benefits should be considered when deciding between treatment with raloxifene hydrochloride and other therapies for postmenopausal women.

DOWNLOAD DRUG LEAFLET

WHERE TO FIND

PUBLIC MARKET
PRIVATE MARKET

Insira seu cep e confira as lojas mais próximas de você!

*Item não encontrado, tente novamente.

CONTRAINDICATIONS:

Raloxifene hydrochloride is contraindicated in women who are pregnant or may become pregnant. Treatment with raloxifene hydrochloride during pregnancy increases the risk of problems with fetal development.

Raloxifene hydrochloride is contraindicated in patients who have or have had venous thromboembolic events (clotted blood in the vein), including deep vein thrombosis, pulmonary embolism (blockage of a vessel in the lung), and retinal vein thrombosis.

Raloxifene hydrochloride is contraindicated in patients with allergy to raloxifene hydrochloride or to any of the ingredients of the formulation.

This medicine should not be used by women who are pregnant or may become pregnant during treatment.

  • FOLLOW US ON SOCIAL MIDIAS:

Rua Joaquim Faustino de Camargo, 201, Jardim São Paulo, Taboão da Serra - SP (11) 4138-8200 • © Blanver 2020, Todos os direitos reservados